PMID- 21920388
OWN - NLM
STAT- MEDLINE
DCOM- 20120208
LR  - 20111025
IS  - 1872-9096 (Electronic)
IS  - 0166-3542 (Linking)
VI  - 92
IP  - 2
DP  - 2011 Nov
TI  - Characterization of drug-resistance mutations in HBV D-genotype chronically 
      infected patients, naive to antiviral drugs.
PG  - 382-5
LID - 10.1016/j.antiviral.2011.08.013 [doi]
AB  - Presence of drug-resistance mutations in drug-naive hepatitis B virus (HBV) 
      infected patients can seriously compromise response to antiviral treatment. 
      Therefore, our study was aimed at defining the prevalence of HBV drug-resistance 
      in a population of 140 patients, all infected with HBV-D-genotype (the most 
      common HBV-genotype in Eastern Europe, Mediterranean countries and Middle East) 
      and naive to antiviral therapy. HBV reverse-transcriptase (RT) region was 
      sequenced and analyzed for 20 mutations, confirmed by in vitro studies as 
      associated with resistance to nucleos(t)ide HBV-RT inhibitors 
      (rtL80I/V-rtI169T-rtV173L-rtL180M-rtA181T/V/S-rtT184A/S/G/C-rtA194T-rtS202C/G/I-rtM204V/I-rtN236T-rtM250V). 
      Amino acid changes at other six RT positions, potentially associated with 
      resistance, were also analyzed (rtV84M-rtV191I-rtV207L-rtV214A-rtQ215S-rtI233V). 
      Overall, only 2/140 (1.4%) patients carried primary drug-resistance mutations 
      [rtA181V (0.7%), and rtA194T (0.7%)], while 3/140 (2.1%) patients harbored the 
      secondary mutations rtV173L (1.4%) and rtL180M (0.7%). Additionally, five 
      polymorphic mutations, with a suggested role in drug resistance, were detected 
      [rtQ215S (12.8%), rtI233V (4.3%), rtV214A (3.6%), rtV191I (0.7%), rtV207L 
      (0.7%)]. Notably, no YMDD mutations, namely rtM204V/I, were found. Taken 
      together, the rate of important drug resistance mutations in naive HBV D-genotype 
      infected patients is today very low, and suggests the potential full efficacy of 
      new-generation antiviral drugs used in first line therapy. Whether such low rate 
      can be extrapolated to non HBV-D subtypes, requires a detailed investigation to 
      be performed in a different cohort of patients.
CI  - Copyright (c) 2011 Elsevier B.V. All rights reserved.
FAU - Salpini, R
AU  - Salpini R
AD  - Department of Experimental Medicine and Biochemical Science, University of Tor 
      Vergata, Via Montpellier 1, 00100 Rome, Italy.
FAU - Svicher, V
AU  - Svicher V
FAU - Cento, V
AU  - Cento V
FAU - Gori, C
AU  - Gori C
FAU - Bertoli, A
AU  - Bertoli A
FAU - Scopelliti, F
AU  - Scopelliti F
FAU - Micheli, V
AU  - Micheli V
FAU - Cappiello, T
AU  - Cappiello T
FAU - Spano, A
AU  - Spano A
FAU - Rizzardini, G
AU  - Rizzardini G
FAU - De Sanctis, G M
AU  - De Sanctis GM
FAU - Sarrecchia, C
AU  - Sarrecchia C
FAU - Angelico, M
AU  - Angelico M
FAU - Perno, C F
AU  - Perno CF
LA  - eng
SI  - GENBANK/JN225963
SI  - GENBANK/JN225964
SI  - GENBANK/JN225965
SI  - GENBANK/JN225966
SI  - GENBANK/JN225967
SI  - GENBANK/JN225968
SI  - GENBANK/JN225969
SI  - GENBANK/JN225970
SI  - GENBANK/JN225971
SI  - GENBANK/JN225972
SI  - GENBANK/JN225973
SI  - GENBANK/JN225974
SI  - GENBANK/JN225975
SI  - GENBANK/JN225976
SI  - GENBANK/JN225977
SI  - GENBANK/JN225978
SI  - GENBANK/JN225979
SI  - GENBANK/JN225980
SI  - GENBANK/JN225981
SI  - GENBANK/JN225982
SI  - GENBANK/JN225983
SI  - GENBANK/JN225984
SI  - GENBANK/JN225985
SI  - GENBANK/JN225986
SI  - GENBANK/JN225987
SI  - GENBANK/JN225988
SI  - GENBANK/JN225989
SI  - GENBANK/JN225990
SI  - GENBANK/JN225991
SI  - GENBANK/JN225992
SI  - GENBANK/JN225993
SI  - GENBANK/JN225994
SI  - GENBANK/JN225995
SI  - GENBANK/JN225996
SI  - GENBANK/JN225997
SI  - GENBANK/JN225998
SI  - GENBANK/JN225999
SI  - GENBANK/JN226000
SI  - GENBANK/JN226001
SI  - GENBANK/JN226002
SI  - GENBANK/JN226003
SI  - GENBANK/JN226004
SI  - GENBANK/JN226005
SI  - GENBANK/JN226006
SI  - GENBANK/JN226007
SI  - GENBANK/JN226008
SI  - GENBANK/JN226009
SI  - GENBANK/JN226010
SI  - GENBANK/JN226011
SI  - GENBANK/JN226012
SI  - GENBANK/JN226013
SI  - GENBANK/JN226014
SI  - GENBANK/JN226015
SI  - GENBANK/JN226016
SI  - GENBANK/JN226017
SI  - GENBANK/JN226018
SI  - GENBANK/JN226019
SI  - GENBANK/JN226020
SI  - GENBANK/JN226021
SI  - GENBANK/JN226022
SI  - GENBANK/JN226023
SI  - GENBANK/JN226024
SI  - GENBANK/JN226025
SI  - GENBANK/JN226026
SI  - GENBANK/JN226027
SI  - GENBANK/JN226028
SI  - GENBANK/JN226029
SI  - GENBANK/JN226030
SI  - GENBANK/JN226031
SI  - GENBANK/JN226032
SI  - GENBANK/JN226033
SI  - GENBANK/JN226034
SI  - GENBANK/JN226035
SI  - GENBANK/JN226036
SI  - GENBANK/JN226037
SI  - GENBANK/JN226038
SI  - GENBANK/JN226039
SI  - GENBANK/JN226040
SI  - GENBANK/JN226041
SI  - GENBANK/JN226042
SI  - GENBANK/JN226043
SI  - GENBANK/JN226044
SI  - GENBANK/JN226045
SI  - GENBANK/JN226046
SI  - GENBANK/JN226047
SI  - GENBANK/JN226048
SI  - GENBANK/JN226049
SI  - GENBANK/JN226050
SI  - GENBANK/JN226051
SI  - GENBANK/JN226052
SI  - GENBANK/JN226053
SI  - GENBANK/JN226054
SI  - GENBANK/JN226055
SI  - GENBANK/JN226056
SI  - GENBANK/JN226057
SI  - GENBANK/JN226058
SI  - GENBANK/JN226059
SI  - GENBANK/JN226060
SI  - GENBANK/JN226061
SI  - GENBANK/JN226062
SI  - GENBANK/JN226063
SI  - GENBANK/JN226064
SI  - GENBANK/JN226065
SI  - GENBANK/JN226066
SI  - GENBANK/JN226067
SI  - GENBANK/JN226068
SI  - GENBANK/JN226069
SI  - GENBANK/JN226070
SI  - GENBANK/JN226071
SI  - GENBANK/JN226072
SI  - GENBANK/JN226073
SI  - GENBANK/JN226074
SI  - GENBANK/JN226075
SI  - GENBANK/JN226076
SI  - GENBANK/JN226077
SI  - GENBANK/JN226078
SI  - GENBANK/JN226079
SI  - GENBANK/JN226080
SI  - GENBANK/JN226081
SI  - GENBANK/JN226082
SI  - GENBANK/JN226083
SI  - GENBANK/JN226084
SI  - GENBANK/JN226085
SI  - GENBANK/JN226086
SI  - GENBANK/JN226087
SI  - GENBANK/JN226088
SI  - GENBANK/JN226089
SI  - GENBANK/JN226090
SI  - GENBANK/JN226091
SI  - GENBANK/JN226092
SI  - GENBANK/JN226093
SI  - GENBANK/JN226094
SI  - GENBANK/JN226095
SI  - GENBANK/JN226096
SI  - GENBANK/JN226097
SI  - GENBANK/JN226098
SI  - GENBANK/JN226099
PT  - Journal Article
DEP - 20110905
PL  - Netherlands
TA  - Antiviral Res
JT  - Antiviral research
JID - 8109699
RN  - 0 (Antiviral Agents)
RN  - 0 (DNA, Viral)
RN  - 0 (Viral Proteins)
RN  - EC 2.7.7.49 (RNA-Directed DNA Polymerase)
SB  - IM
MH  - Adult
MH  - Amino Acid Substitution
MH  - Antiviral Agents/*pharmacology
MH  - DNA Mutational Analysis
MH  - DNA, Viral/chemistry/genetics
MH  - *Drug Resistance, Viral
MH  - Europe, Eastern
MH  - Genotype
MH  - Hepatitis B virus/classification/*drug effects/genetics/*isolation & purification
MH  - Hepatitis B, Chronic/*virology
MH  - Humans
MH  - Mediterranean Region
MH  - Middle Aged
MH  - Middle East
MH  - Molecular Sequence Data
MH  - *Mutation, Missense
MH  - Prevalence
MH  - RNA-Directed DNA Polymerase/genetics
MH  - Sequence Analysis, DNA
MH  - Viral Proteins/genetics
EDAT- 2011/09/17 06:00
MHDA- 2012/02/09 06:00
CRDT- 2011/09/17 06:00
PHST- 2011/03/31 00:00 [received]
PHST- 2011/07/12 00:00 [revised]
PHST- 2011/08/16 00:00 [accepted]
PHST- 2011/09/17 06:00 [entrez]
PHST- 2011/09/17 06:00 [pubmed]
PHST- 2012/02/09 06:00 [medline]
AID - S0166-3542(11)00414-1 [pii]
AID - 10.1016/j.antiviral.2011.08.013 [doi]
PST - ppublish
SO  - Antiviral Res. 2011 Nov;92(2):382-5. doi: 10.1016/j.antiviral.2011.08.013. Epub 
      2011 Sep 5.